What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Six analysts have provided ratings for Tarsus Pharmaceuticals (NASDAQ:TARS) in the last quarter, with five being bullish, one somewhat bullish, and none being bearish or indifferent. The average price target is $44.67, indicating a significant upside from the current price of $16.635. The average price target has increased by 2.69% over the past month.
August 14, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are bullish on Tarsus Pharmaceuticals, indicating a potential upside for the stock.
The bullish sentiment from analysts, along with the significant upside indicated by the average price target, suggests a positive short-term impact on Tarsus Pharmaceuticals' stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100